De azi:

In final guidance published today (15 March) NICE has recommended dabigatran [...], in accordance with its licensed indications, as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation. The guidance also recommends that the decision about whether to start treatment with dabigatran should be made after an informed discussion about the risks and benefits of dabigatran compared with warfarin, and in light of a person's current level of international normalised ratioⁱ(INR) control if they are already taking warfarin.

Sursa: NICE